Why is Bliss GVS Pharma falling/rising?

As of 02-Jul, Bliss GVS Pharma Ltd is currently priced at 154.95, reflecting an increase of 0.6 (0.39%). The stock has shown strong performance in the short term, with a 3.75% rise over the past week and a notable 15.20% increase over the last month, significantly outperforming the Sensex, which rose by only 0.79% and 2.50% respectively. However, despite this recent uptick, the company has faced challenges, including a decline in profits by 19.5% over the past year and negative results for the last three consecutive quarters. The stock is trading at a premium compared to its peers, and while it has a low debt-to-equity ratio and a fair valuation, the long-term growth outlook is hindered by a -2.54% annual decline in operating profit over the last five years.
In the broader market context, Bliss GVS Pharma's recent performance has been strong relative to the benchmark, particularly in the near term, where it has outperformed the Sensex. Despite this, the stock's year-to-date performance shows a decline of 5.89%, contrasting with the Sensex's gain of 6.75%. The falling investor participation, as indicated by a 30.21% drop in delivery volume, raises concerns about liquidity and market confidence. Additionally, the lack of domestic mutual fund investment may suggest hesitance among institutional investors regarding the stock's valuation and business prospects, which could impact its future performance.